Immunogen Profit Margin

The latest profit margin for IMGN is -25.41% as of September 2023. That compares with -2.1% in the prior-year period — up 87.9% year over year. That is below the Healthcare sector average of 15.58%. Investors often review this figure alongside Immunogen's historical trend and sector peers before judging valuation or financial health.

Over the past year, IMGN's profit margin moved from -2.1% to -25.41% — a 87.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Immunogen's valuation or profitability profile.

Against Healthcare companies, IMGN currently prints -25.41% for profit margin, while the sector average sits near 15.58%. That is roughly 263.0% below the sector mean. Large gaps often invite a closer look at Immunogen's growth, margins, and balance sheet.

Profit Margin shows how effectively Immunogen converts resources into returns. At -25.41%, IMGN may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -2.1% in the prior-year period — up 87.9% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting IMGN's profit margin (-25.41%), review year-over-year change from -2.1%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.